Union Ministry of Health and Family Welfare Proposes Amendments to Medical Devices Rules, 2017 to Promote Ease of Doing Business

1. At a Glance

• Union Ministry of Health and Family Welfare (MoHFW) has proposed draft amendments to the Medical Devices Rules, 2017 aimed at improving Ease of Doing Business (EoDB) and streamlining the medical device licensing process. [1]
• Core change: rationalizing timelines for grant of manufacturing licences across different risk categories of medical devices. [1]
• Relevant for Prelims (drug/medical device regulatory architecture) and Mains GS-II/GS-III (health governance, regulatory reform, manufacturing ecosystem).
• Reflects the broader government push (seen also in NDCT Rules 2019 amendments) to reduce regulatory burden while retaining safety/quality standards. [3]

2. Why in the News

• MoHFW released a draft notification proposing amendments to the Medical Devices Rules, 2017, placed in the public domain via the Official Gazette and the CDSCO website for stakeholder comments. [1]
• The proposal follows a pattern of recent regulatory streamlining, similar to the 2025 amendments to the New Drugs and Clinical Trials (NDCT) Rules, 2019, also framed around reducing regulatory burden and promoting EoDB. [3]

3. Background & Evolution

• Medical devices in India were historically regulated as "drugs" under the Drugs and Cosmetics Act, 1940, with devices notified individually. [6]
• Medical Devices Rules, 2017 notified by the Health Ministry, came into effect 1 January 2018, providing a dedicated risk-based regulatory framework for medical devices (distinct from pharmaceuticals). [2][5]
• 1 October 2022: Licensing regime extended to Class A and Class B (low/low-moderate risk) devices, completing phased implementation of the risk-based classification system. [4]
• 2022: Draft National Medical Devices Policy, 2022 released; later the Cabinet approved the Policy for the Medical Devices Sector, aiming to grow the sector and improve regulatory ease. [7][8]
• Current (2025-26) proposal: further amendment of the 2017 Rules to rationalize licensing timelines — the latest step in this continuing reform trajectory. [1]

4. Core Static Facts

Item	Detail
Nodal Ministry	Union Ministry of Health and Family Welfare (MoHFW) [1]
Regulator	Central Drugs Standard Control Organisation (CDSCO) [6]
Enabling Act	Drugs and Cosmetics Act, 1940 [6]
Governing Rules	Medical Devices Rules, 2017 (effective 1 Jan 2018) [2]
Risk classes	Class A (low), Class B (low-moderate), Class C (moderate-high), Class D (high) [6]
Licensing authority (Class A & B)	State Licensing Authorities, after Quality Management System audit by an accredited Notified Body [6]
Licensing authority (Class C & D)	Central Licensing Authority (CDSCO) — implied by classification structure [6]
Exemption	Class A non-sterile, non-measuring devices exempted from manufacturing/import licence; only online registration required [6]
Examples of Class C/D devices	Cardiac stents, hip and knee implants, orthopaedic implants [6]
Proposed change (2025-26)	Rationalized/defined timelines for each licensing stage — application scrutiny, notified body audit, compliance verification, licence issuance [1]
Status	Draft notification for public comments, published in Official Gazette and on CDSCO website [1]

5. Multi-Dimensional Analysis

Economic

• Faster licence approvals reduce time-to-market for domestic manufacturers, supporting India's push for medical device manufacturing self-reliance and import substitution. [1]
• Aligns with Make in India and PLI-scheme objectives for medical devices, indirectly boosting investment and employment in the sector.

Administrative/Governance

• Introduces defined, stage-wise timelines (application scrutiny → notified body audit → compliance verification → licence issuance), enhancing transparency and predictability in a previously discretion-heavy process. [1]
• Continues the phased federal structure of licensing: State Licensing Authorities for lower-risk devices, Central authority for high-risk devices. [6]

Legal/Regulatory

• Amendment is being carried out through delegated legislation (rule amendment under the Drugs and Cosmetics Act, 1940) rather than fresh primary legislation — a recurring pattern in Indian health regulation. [6]
• Public consultation via Gazette notification reflects the standard rule-making procedure under the Act.

Social/Public Health

• Balancing EoDB with patient safety: amendments explicitly state that safety, quality, and performance standards will be maintained despite reduced timelines. [1]

Scientific/Technological

• Reinforces risk-based classification (global harmonization approach, similar to WHO/GHTF-aligned systems) rather than blanket regulation, aiding technologically sound device oversight. [6]

6. Recent Developments (last 12-18 months)

• MoHFW/CDSCO published the draft amendment proposal to the Medical Devices Rules, 2017 for public comments (2025-26 timeframe), focused on licence timeline rationalization. [1]
• Comparable regulatory streamlining seen in 2025 with amendments to NDCT Rules, 2019, indicating a ministry-wide EoDB regulatory reform drive. [3]

7. Prelims Hooks

• Medical Devices Rules notified in 2017, effective from 1 January 2018. [2]
• Nodal regulator for medical devices: CDSCO (Central Drugs Standard Control Organisation), under MoHFW — not a separate standalone body. [6]
• Enabling parent legislation: Drugs and Cosmetics Act, 1940 (medical devices are legally treated as "drugs" under this Act). [6]
• Four risk classes: A (low), B (low-moderate), C (moderate-high), D (high). [6]
• Licensing of Class A & B devices extended to full effect from 1 October 2022. [4]
• Class A non-sterile, non-measuring devices need only online registration, not a licence. [6]
• Class C/D examples: cardiac stents, hip/knee implants. [6]
• Class A & B licences granted by State Licensing Authorities after audit by an accredited Notified Body. [6]
• Latest (2025-26) proposed amendment targets licensing timelines, not classification itself. [1]
• Draft notification process: published in Official Gazette and on CDSCO website for public comments. [1]
• Draft National Medical Devices Policy released in 2022, followed by Cabinet approval of a Policy for the Medical Devices Sector. [7][8]

8. Mains Relevance

• GS-II: Government policies and interventions for development in health sector; issues relating to health governance and regulatory bodies.
• GS-III: Indigenization of technology and developing new technology; effects of liberalization on the economy; industry and infrastructure — medical device manufacturing ecosystem.
• Possible question stems: 1. "Discuss the regulatory evolution of medical devices in India from being treated as 'drugs' to a risk-based classification system. How do the proposed 2025-26 amendments to the Medical Devices Rules, 2017 seek to balance ease of doing business with patient safety?" 2. "Examine the federal structure of medical device licensing in India, distinguishing the roles of State and Central Licensing Authorities." 3. "'Regulatory delay is a hidden tax on innovation.' Discuss in the context of recent Indian health-sector regulatory reforms (Medical Devices Rules, NDCT Rules)."

9. Related Topics to Study Next

• National Medical Devices Policy, 2022 — parent policy framework shaping the sector's growth strategy. [7]
• New Drugs and Clinical Trials (NDCT) Rules, 2019 amendments — parallel EoDB reform in pharma regulation. [3]
• Drugs and Cosmetics Act, 1940 — the statutory backbone for all device/drug regulation.
• PLI Scheme for Medical Devices — economic complement to regulatory ease, boosting domestic manufacturing.
• CDSCO structure and functions — India's apex drug/device regulator.
• Ayushman Bharat Health Infrastructure Mission — broader health infrastructure context.
• Ease of Doing Business (EoDB) reforms across ministries — comparative regulatory streamlining trend.

10. Common Errors / Trap Areas

• Confusing CDSCO with an independent statutory regulator — it functions under MoHFW, not as an autonomous body like SEBI/RBI.
• Assuming medical devices have their own dedicated Act — they are regulated as "drugs" under the Drugs and Cosmetics Act, 1940, with Medical Devices Rules, 2017 as subordinate legislation.
• Mixing up licensing authority: State authorities handle Class A/B; Central authority (CDSCO) handles Class C/D — a frequently tested distinction.
• Confusing the 2025-26 licensing-timeline amendment with the 2022 Class A/B licensing rollout — these are separate reform milestones.
• Assuming this is a new standalone Act — it is a proposed amendment to existing subordinate rules (2017 Rules), currently only in draft/consultation stage, not yet notified.